Metabolomics in diagnosis and biomarker discovery of colorectal cancer

Cancer Letters

Volumn 345, Issue 1, 2014, Pages 17-20

  Zhang, Aihua ^a   Sun, Hui ^a   Yan, Guangli ^a   Wang, Ping ^a   Han, Ying ^a   Wang, Xijun ^a  

^a HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Biomarkers; Colorectal cancer; Early diagnosis; Metabolites; Metabolomics

Indexed keywords

TUMOR MARKER;

CANCER SCREENING; CANCER STAGING; COLONOSCOPY; COLORECTAL CANCER; DISEASE SEVERITY; EARLY DIAGNOSIS; HUMAN; METABOLITE; METABOLOME; METABOLOMICS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SURVIVAL RATE;

BIOMARKERS; COLORECTAL CANCER; EARLY DIAGNOSIS; METABOLITES; METABOLOMICS;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; METABOLOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893788207     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.011     Document Type: Review

References (51)

1. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., Allen B., Bozic I., Reiter J.G., Nowak M.A., Kinzler K.W., Oliner K.S., Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486(7404):537-540.
2. Krzystek-Korpacka M., Diakowska D., Kapturkiewicz B., Bebenek M., Gamian A. Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett. 2013, 337(1):107-114.
3. Krimpenfort P., Song J.Y., Proost N., Zevenhoven J., Jonkers J., Berns A. Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature 2012, 482(7386):538-541.
4. Janakiram N.B., Mohammed A., Rao C.V. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev. 2011, 30(3-4):507-523.
5. Chan E.C., Koh P.K., Mal M., Cheah P.Y., Eu K.W., Backshall A., Cavill R., Nicholson J.K., Keun H.C. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome. Res. 2009, 8(1):352-361.
6. Ma Y.L., Qin H.L., Liu W.J., Peng J.Y., Huang L., Zhao X.P., Cheng Y.Y. Ultra-high performance liquid chromatography-mass spectrometry for the metabolomic analysis of urine in colorectal cancer. Dig. Dis. Sci. 2009, 54(12):2655-2662.
7. Qiu Y., Cai G., Su M., Chen T., Liu Y., Xu Y., Ni Y., Zhao A., Cai S., Xu L.X., Jia W. Urinary metabonomic study on colorectal cancer. J. Proteome. Res. 2010, 9(3):1627-1634.
8. Mirnezami R., Kinross J.M., Vorkas P.A., Goldin R., Holmes E., Nicholson J., Darzi A. Implementation of molecular phenotyping approaches in the personalized surgical patient journey. Ann. Surg. 2012, 255(5):881-889.
9. Zhang A., Sun H., Han Y., Yan G., Wang X. Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system. PLoS One 2013, 8(5). e64381. 6.
10. Zhang A.H., Sun H., Qiu S., Wang X.J. NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis. Magn. Reson. Chem. 2013, 51(9):549-556.
11. Jobard E., Pontoizeau C., Blaise B.J., Bachelot T., Elena-Herrmann B., Trédan O. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett. 2013, doi:pii: S0304-3835(13)00664-2.
12. Zhang A., Sun H., Han Y., Yuan Y., Wang P., Song G., Yuan X., Zhang M., Xie N., Wang X. Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach. Analyst 2012, 137(18):4200-4208.
13. Yoo B.C., Kong S.Y., Jang S.G., Kim K.H., Ahn S.A., Park W.S., Park S., Yun T., Eom H.S. Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling. BMC Cancer 2010, 10:55.
14. Zhang A.H., Sun H., Qiu S., Wang X.J. Metabolomics in noninvasive breast cancer. Clin. Chim. Acta 2013, 424:3-7.
15. 1H NMRS-based metabolomics study. Cancer Res. 2009, 69(9):3731-3735.
16. Gomez-Santos L., Luka Z., Wagner C., Fernandez-Alvarez S., Lu S.C., Mato J.M., Martinez-Chantar M.L., Beraza N. Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase. Hepatology 2012, 56(2):747-759.
17. Wang X., Zhang A., Wang P., Sun H., Wu G., Sun W., Lv H., Jiao G., Xu H., Yuan Y., Liu L., Zou D., Wu Z., Han Y., Yan G., Dong W., Wu F., Dong T., Yu Y., Zhang S., Wu X., Tong X., Meng X. Metabolomics coupled with proteomics advancing drug discovery toward more agile development of targeted combination therapies. Mol. Cell Proteomics. 2013, 12(5):1226-1238.
18. Holmes E., Loo R.L., Stamler J., Bictash M., Yap I.K., Chan Q., Ebbels T., De Iorio M., Brown I.J., Veselkov K.A., Daviglus M.L., Kesteloot H., Ueshima H., Zhao L., Nicholson J.K. P Elliott. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008, 453:396-401.
19. Zhang A., Sun H., Yan G., Han Y., Ye Y., Wang X. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin. Chim. Acta 2013, 418:86-90.
20. Zhang A.H., Wang P., Sun H., Yan G.L., Han Y., Wang X.J. High-throughput ultra-performance liquid chromatography-mass spectrometry characterization of metabolites guided by a bioinformatics program. Mol. Biosyst. 2013, 9(9):2259-2265.
21. Moazzami A.A., Zhang J.X., Kamal-Eldin A., Aman P., Hallmans G., Johansson J.E., Andersson S.O. Nuclear magnetic resonance-based metabolomics enable detection of the effects of a whole grain rye and rye bran diet on the metabolic profile of plasma in prostate cancer patients. J. Nutr. 2011, 141(12):2126-2132.
22. Sun H., Zhang A., Yan G., Piao C., Li W., Sun C., Wu X., Li X., Chen Y., Wang X. Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews. Mol. Cell Proteomics. 2013, 12(3):710-719.
23. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
24. Wang X., Zhang A., Han Y., Wang P., Sun H., Song G., Dong T., Yuan Y., Yuan X., Zhang M., Xie N., Zhang H., Dong H., Dong W. Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease. Mol. Cell Proteomics. 2012, 11(8):370-380.
25. Gu H., Pan Z., Xi B., Asiago V., Musselman B., Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. Anal. Chim. Acta 2011, 686(1-2):57-63.
26. Malet-Martino M., Holzgrabe U. NMR techniques in biomedical and pharmaceutical analysis. J. Pharm. Biomed. Anal. 2011, 55(1):1-15.
27. Zhang A.H., Sun H., Wang X.J. Recent advances in metabolomics in neurological disease, and future perspectives. Anal. Bioanal. Chem. 2013, 405(25):8143-8150.
28. Wang X., Zhang A., Sun H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology 2013, 57(5):2072-2077.
29. Zhang A., Sun H., Wang X. Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment. Appl. Biochem. Biotechnol. 2012, 168(6):1718-1727.
30. Sugimoto M., Wong D.T., Hirayama A., Soga T., Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010, 6(1):78-95.
31. Zhang A., Sun H., Wu X., Wang X. Urine metabolomics. Clin. Chim. Acta 2012, 414:65-69.
32. Kleiner M., Wentrup C., Lott C., Teeling H., Wetzel S., Young J., Chang Y.J., Shah M., VerBerkmoes N.C., Zarzycki J., Fuchs G., Markert S., Hempel K., Voigt B., Becher D., Liebeke M., Lalk M., Albrecht D., Hecker M., Schweder T., Dubilier N. Metaproteomics of a gutless marine worm and its symbiotic microbial community reveal unusual pathways for carbon and energy use. Proc. Natl. Acad. Sci. USA 2012, 109(19):E1173-82.
33. Wang X., Zhang A., Sun H. Future perspectives of Chinese medical formulae: chinmedomics as an effector. OMICS 2012, 16(7-8):414-421.
34. Rivas-Ubach A., Sardans J., Pérez-Trujillo M., Estiarte M., Peñuelas J. Strong relationship between elemental stoichiometry and metabolome in plants. Proc. Natl. Acad. Sci. USA 2012, 109(11):4181-4186.
35. Zhang A., Sun H., Wang X. Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal. Bioanal. Chem. 2012, 404(4):1239-1245.
36. Finley L.W., Lee J., Souza A., Desquiret-Dumas V., Bullock K., Rowe G.C., Procaccio V., Clish C.B., Arany Z., Haigis M.C. Skeletal muscle transcriptional coactivator PGC-1α mediates mitochondrial, but not metabolic, changes during calorie restriction. Proc. Natl. Acad. Sci. USA 2012, 109(8):2931-2936.
37. Mintz-Oron S., Meir S., Malitsky S., Ruppin E., Aharoni A., Shlomi T. Reconstruction of Arabidopsis metabolic network models accounting for subcellular compartmentalization and tissue-specificity. Proc. Natl. Acad. Sci. USA 2012, 109(1):339-344.
38. Lange B.M., Mahmoud S.S., Wildung M.R., Turner G.W., Davis E.M., Lange I., Baker R.C., Boydston R.A., Croteau R.B. Improving peppermint essential oil yield and composition by metabolic engineering. Proc. Natl. Acad. Sci. USA 2011, 108(41):16944-16949.
39. Ward J.L., Baker J.M., Llewellyn A.M., Hawkins N.D., Beale M.H. Metabolomic analysis of Arabidopsis reveals hemiterpenoid glycosides as products of a nitrate ion-regulated, carbon flux overflow. Proc. Natl. Acad. Sci. USA 2011, 108(26):10762-10767.
40. Leichtle A.B., Nuoffer J.M., Ceglarek U., Kase J., Conrad T., Witzigmann H., Thiery J., Fiedler G.M. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics 2012, 8(4):643-653.
41. Nishiumi S., Kobayashi T., Ikeda A., Yoshie T., Kibi M., Izumi Y., Okuno T., Hayashi N., Kawano S., Takenawa T., Azuma T. Yoshida M.A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 2012, 7(7):e40459.
42. Farshidfar F., Weljie A.M., Kopciuk K., Buie W.D., Maclean A., Dixon E., Sutherland F.R., Molckovsky A., Vogel H.J., Bathe O.F. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med. 2012, 4(5):42.
43. Mal M., Koh P.K., Cheah P.Y., Chan E.C. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal. Bioanal. Chem. 2012, 403(2):483-493.
44. Ma Y., Zhang P., Wang F., Liu W., Yang J., Qin H. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann. Surg. 2012, 255(4):720-730.
45. Cheng Y., Xie G., Chen T., Qiu Y., Zou X., Zheng M., Tan B., Feng B., Dong T., He P., Zhao L., Zhao A., Xu L.X., Zhang Y., Jia W. Distinct urinary metabolic profile of human colorectal cancer. J. Proteome. Res. 2012, 11(2):1354-1363.
46. Bertini I., Cacciatore S., Jensen B.V., Schou J.V., Johansen J.S., Kruhøffer M., Luchinat C., Nielsen D.L., Turano P. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 2012, 72(1):356-364.
47. Ritchie S.A., Ahiahonu P.W., Jayasinghe D., Heath D., Liu J., Lu Y., Jin W., Kavianpour A., Yamazaki Y., Khan A.M., Hossain M., Su-Myat K.K., Wood P.L., Krenitsky K., Takemasa I., Miyake M., Sekimoto M., Monden M., Matsubara H., Nomura F., Goodenowe D.B. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010, 8:13.
48. Ong E.S., Zou L., Li S., Cheah P.Y., Eu K.W., Ong C.N. Metabolic profiling in colorectal cancer reveals signature metabolic shifts during tumorigenesis. Mol. Cell Proteomics. 2010, [Epub ahead of print].
49. Ma Y., Liu W., Peng J., Huang L., Zhang P., Zhao X., Cheng Y., Qin H. A pilot study of gas chromatograph/mass spectrometry-based serum metabolic profiling of colorectal cancer after operation. Mol. Biol. Rep. 2010, 37(3):1403-1411.
50. Monleón D., Morales J.M., Barrasa A., López J.A., Vázquez C., Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009, 22(3):342-348.
51. Tomita M., Kami K. Cancer. Systems biology, metabolomics, and cancer metabolism. Science 2012, 336(6084):990-991.